Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eledon Pharmaceuticals, Inc. on August 2, 2021, covering events occurring on July 31, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol ELDN.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is a leadership transition within the finance department effective July 31, 2021:
- Resignation: Jon Kuwahara resigned as Senior Vice President, Finance & Administration and Principal Accounting Officer.
- Appointment: Paul Little was appointed as the new Principal Accounting Officer.
- Continuity: Paul Little continues to serve as the Company's Chief Financial Officer and Principal Financial Officer.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The report states there are no family relationships between Mr. Little and other officers/directors, and no undisclosed arrangements regarding his appointment.
Key Facts for Investors
- Jon Kuwahara has departed the company as of July 31, 2021.
- Paul Little has assumed the role of Principal Accounting Officer while retaining his CFO title.
- No financial data or operational updates are included in this specific filing.